How to reduce the treatment gap for XXXX with @entity302 in resource-limited settings by innovative galenic formulations: A review of the current situation, overview of potential techniques, interests and limits.

@entity1 @entity16 @entity1092 @entity109 @entity302 @entity3174 @entity2049
UNASSIGNED: @entity302 is a chronic @entity16 affecting more than 69 million @entity1 worldwide, nearly 90% of them in low and middle-income countries (LMICs). In those countries, only four major antiepileptic drugs are commonly used: @entity109 , @entity2049 , @entity1092 and @entity3174 . There are also problems with the accessibility, availability and quality of drugs. The main objective was to review the literature concerning "long" sustained-release formulations of AEDs that have the potential to reduce the number of administrations and help overcome problems of compliance, accessibility and the treatment gap. The main endpoint was a releasing of the active ingredient over more than 24h. We also assessed the feasibility and acceptability in resource-limited settings. Two drugs were found in unconventional release formulations: @entity2049 and @entity1092 ; but they were not "long" sustained release because they required administration once a day. Several techniques were available, including: esterification, transdermal devices, liposomes and polymeric devices preformed or formed in situ. In situ methods for the preparation of injectable biodegradable microparticles or implants for controlled delivery seemed best suited to the objective. Furthermore, they appear to fulfil the requirements of feasibility and cost. @entity1092 appeared as well to be a relevant candidate for a "long" sustained release formulation that would improve access to medicines for @entity1 with @entity302 in resource-limited settings. .
